SILVERNAIL LAUREN P

CIK 00012257556 companiesEMERYVILLE, CA

SEC Profile

Transactions

Companies

Filings

CIK

0001225755

Recent Transactions

50 trades

Disposition to Issuer
DYNAVAX TECHNOLOGIES CORP$DVAX
Stock Option (Right to Buy)
2026-02-10−42,750→ 0 total
Disposition to Issuer
DYNAVAX TECHNOLOGIES CORP$DVAX
Common Stock - Restricted Stock Units
2026-02-10−10,075→ 0 total
Disposition to Issuer
DYNAVAX TECHNOLOGIES CORP$DVAX
Stock Option (Right to Buy)
2026-02-10−7,125→ 0 total
Award
HARROW, INC.$HROW
RSU
2025-06-20+7,339→ 7,339 total
Award
DYNAVAX TECHNOLOGIES CORP$DVAX
Stock Option (Right to Buy)
2025-06-11+7,125→ 7,125 total
Award
DYNAVAX TECHNOLOGIES CORP$DVAX
Common Stock
2025-06-11+1,439→ 10,075 total
Award
DYNAVAX TECHNOLOGIES CORP$DVAX
Stock Option (Right to Buy)
2025-02-03+42,750→ 42,750 total
Award
DYNAVAX TECHNOLOGIES CORP$DVAX
Restricted Stock Unit
2025-02-03+8,636→ 8,636 total
Award
HARROW, INC.$HROW
RSU
2024-06-14+8,347→ 8,347 total
Disposition to Issuer
Harpoon Therapeutics, Inc.
Director Stock Option (Right to Buy)
2024-03-11−2,033→ 0 total
Disposition to Issuer
Harpoon Therapeutics, Inc.
Common Stock
2024-03-11−5,000→ 0 total
Disposition to Issuer
Harpoon Therapeutics, Inc.
Director Stock Option (Right to Buy)
2024-03-11−2,300→ 0 total
Award
HARROW, INC.$HROW
RSU
2024-01-26+3,119→ 3,119 total
Award
Harpoon Therapeutics, Inc.
Common Stock
2023-11-27+5,000→ 5,000 total
Award
Harpoon Therapeutics, Inc.
Director Stock Option (Right to Buy)
2023-06-22+23,000→ 23,000 total
Award
Harpoon Therapeutics, Inc.
Director Stock Option (right to buy)
2022-09-15+20,335→ 20,335 total
Sale
Evolus, Inc.$EOLS
Common Stock
2022-05-18$12.42/sh−52,015→ 141,571 total
Sale
Evolus, Inc.$EOLS
Common Stock
2022-05-17$13.92/sh−16,189→ 193,586 total
Sale
Evolus, Inc.$EOLS
Common Stock
2022-03-08$9.73/sh−10,192→ 209,775 total
Award
Evolus, Inc.$EOLS
Common Stock
2022-01-24+53,571→ 219,967 total
Award
Evolus, Inc.$EOLS
Stock Option (Right to Buy)
2022-01-24+77,640→ 77,640 total
Sale
Evolus, Inc.$EOLS
Common Stock
2021-08-10$11.18/sh+14,293→ 194,982 total
Sale
Evolus, Inc.$EOLS
Common Stock
2021-08-10$11.18/sh−14,293→ 166,396 total
Award
Evolus, Inc.$EOLS
Common Stock
2021-01-27+90,000→ 180,689 total
Sale
Evolus, Inc.$EOLS
Common Stock
2021-01-25$7.46/sh−2,699→ 90,689 total
Award
Evolus, Inc.$EOLS
Common Stock
2020-05-13+40,000→ 93,388 total
Award
Evolus, Inc.$EOLS
Common Stock
2020-01-23+26,000→ 53,388 total
Award
Evolus, Inc.$EOLS
Stock Option (Right to Buy)
2020-01-23+45,000→ 45,000 total
Sale
Evolus, Inc.$EOLS
Common Stock
2019-05-31$13.53/sh−2,612→ 27,388 total
Award
Evolus, Inc.$EOLS
Stock Option (Right to Buy)
2019-01-23+45,000→ 45,000 total
Award
Evolus, Inc.$EOLS
Stock Option (Right to Buy)
2018-05-29+200,000→ 200,000 total
Award
Evolus, Inc.$EOLS
Common Stock
2018-05-29+30,000→ 30,000 total
Sale
Revance Therapeutics, Inc.
Common Stock
2018-05-22$30.25/sh−2,874→ 65,497 total
Sale
Revance Therapeutics, Inc.
Common Stock
2018-03-22$30.85/sh−3,431→ 68,371 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2018-03-15$31.65/sh−1,152→ 71,802 total
Exercise/Conversion
Revance Therapeutics, Inc.
Common Stock
2018-03-13$8.70/sh+25,867→ 98,821 total
Exercise/Conversion
Revance Therapeutics, Inc.
Stock Option (Right to buy)
2018-03-13+25,867→ 0 total
Sale
Revance Therapeutics, Inc.
Common Stock
2018-03-13$34.50/sh−25,867→ 72,954 total
Exercise/Conversion
Revance Therapeutics, Inc.
Stock Option (Right to buy)
2018-03-09−10,000→ 25,867 total
Exercise/Conversion
Revance Therapeutics, Inc.
Common Stock
2018-03-09$8.70/sh+10,000→ 82,954 total
Sale
Revance Therapeutics, Inc.
Common Stock
2018-03-09$32.50/sh−10,000→ 72,954 total
Sale
Revance Therapeutics, Inc.
Common Stock
2018-03-07$31.50/sh−10,000→ 72,954 total
Exercise/Conversion
Revance Therapeutics, Inc.
Common Stock
2018-03-07$8.70/sh+10,000→ 82,954 total
Exercise/Conversion
Revance Therapeutics, Inc.
Stock Option (Right to buy)
2018-03-07−10,000→ 35,867 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2018-02-15$31.75/sh−1,136→ 72,954 total
Award
Revance Therapeutics, Inc.
Employee Stock Option (Right to Buy)
2018-02-08+48,750→ 48,750 total
Award
Revance Therapeutics, Inc.
Common Stock
2018-02-08+8,125→ 74,090 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2018-01-28$33.50/sh−990→ 65,965 total
Other
Revance Therapeutics, Inc.
Common Stock
2017-12-29$22.99/sh+443→ 66,955 total
Exercise/Conversion
Revance Therapeutics, Inc.
Stock Option (Right to buy)
2017-12-26−17,506→ 45,867 total

SILVERNAIL LAUREN P

Recent Transactions

Companies

Recent Filings

Address